Company news

Tempus AI, Inc. news in 2025

Tempus AI, Inc.'s news releases, calls and decks from 2025, newest first.

View company

Tempus Announces Ten Abstracts Accepted for Presentation at the 2025 San Antonio Breast Cancer Symposium

December 8, 2025

Tempus to Participate in the Piper Sandler 37th Annual Healthcare Conference

November 17, 2025

Tempus and IFLI Announce Study to Advance Follicular Lymphoma Research

November 13, 2025

Tempus Announces Six Abstracts Accepted for Presentation at the Society for Immunotherapy of Cancer Annual Meeting 2025

November 4, 2025

Tempus Reports Third Quarter 2025 Results

November 3, 2025

Tempus to Participate in the Stifel 2025 Healthcare Conference

October 27, 2025

Tempus to Report Third Quarter 2025 Financial Results on November 4

October 20, 2025

Ambry Genetics Announces 10-Year Study in Genetics in Medicine Highlighting the Impact of Proactive Exome Reanalysis for Healthcare Equity

October 19, 2025

Tempus Announces Collaboration with Whitehawk Therapeutics to Advance Biomarker-Driven Oncology Research

October 15, 2025

Tempus Announces Six Abstracts Accepted for Presentation at the European Society for Medical Oncology Congress 2025

October 14, 2025

Tempus Selected by ARPA-H to Provide CRO and Testing Services for the ADAPT Program, Advancing Precision Cancer Therapy

October 8, 2025

Ambry Genetics Announces Improved EHR-Integrated Breast Cancer Risk Assessment Solution with Upgraded Tyrer-Cuzick Scoring Approach Incorporating Breast Density

September 30, 2025

Tempus Receives U.S. FDA 510(k) Clearance for Tempus xR IVD, its RNA NGS In Vitro Diagnostic Device

September 21, 2025

Renalytix Announces Collaboration with Tempus to Advance Intelligent Risk Assessment in Diabetic Kidney Disease

September 14, 2025

Tempus Receives U.S. FDA Special 510(k) Clearance for Updated Tempus Pixel Device

September 10, 2025

Tempus Announces New Study in JCO Precision Oncology Validating PurIST® Algorithm for Enhanced Therapy Selection in Pancreatic Cancer

September 8, 2025

Northwestern Medicine Becomes First Health System to Integrate Tempus’ Generative AI Co-Pilot, David, Into Its EHR Platform

September 3, 2025

Tempus to Participate in Morgan Stanley’s 23rd Annual Global Healthcare Conference

September 2, 2025

Tempus Announces the Acquisition of Paige

August 21, 2025

Tempus Reports Second Quarter 2025 Results

August 7, 2025

Tempus to Report Second Quarter 2025 Financial Results on August 8

July 21, 2025

Tempus Receives U.S. FDA 510(k) Clearance for Tempus ECG-Low EF Software

July 15, 2025

Tempus Expands AI-Enabled Care Pathway Intelligence Platform into Breast Cancer

July 7, 2025

Tempus Announces Pricing of Upsized Offering of $650 Million of Convertible Senior Notes

June 29, 2025

Tempus AI, Inc. Announces Proposed Convertible Senior Notes Offering to Optimize Capital Structure and Reduce Interest Expense

June 29, 2025

Ambry Genetics’ CARE Program Validated for Accuracy in Identifying High-Risk Patients for Hereditary Cancer Testing

June 24, 2025

Tempus to Participate in TD Cowen’s 4th Annual Tools/Dx Revolution Conference

June 16, 2025

Tempus Announces Collaboration with Northwestern University’s Abrams Research Center on Neurogenomics to Leverage AI for Alzheimer’s Disease Research

June 11, 2025

Tempus Introduces xM, An Assay to Monitor Immunotherapy Response for Patients with Advanced Cancers

June 1, 2025

Introducing Tempus One in the EHR with Integrated Guidelines

May 31, 2025

Tempus Introduces Fuses, A Program Designed to Transform Therapeutic Research and Build the Largest Diagnostic Platform Using its Novel Foundation Model

May 30, 2025

Tempus Announces 10 Abstracts Accepted for Presentation at the 2025 American Society of Clinical Oncology Annual Meeting

May 29, 2025

A Decade of Discovery: Tempus Supported Almost 1,500 Research Projects in 10 Years

May 27, 2025

New Study Shows Impact of Ambry Genetics’ Patient for Life™ Program on Rare Disease Diagnosis

May 27, 2025

Tempus to Present at the William Blair 45th Annual Growth Stock Conference

May 20, 2025

Tempus Announces a Collaboration with Verastem to Develop CDx for First-Ever FDA-Approved KRAS-Mutant Recurrent Low-Grade Serous Ovarian Cancer Combination Treatment

May 19, 2025

Tempus Enters Multi-Year Strategic Collaboration With Boehringer Ingelheim to Advance Its Cancer Pipeline

May 13, 2025

Tempus Announces Six Posters Accepted for Presentation at ISPOR 2025

May 12, 2025

Tempus Reports First Quarter 2025 Results

May 5, 2025

Tempus Announces Notetaker, its AI-Powered Clinical Assistant for Psychiatry

May 4, 2025

Tempus TIME Network Expands Support of Phase I Clinical Trials To Accelerate Activation and Enrollment

April 30, 2025

Tempus Publishes Study Validating the Benefits of xF+, its Comprehensive Liquid Biopsy Assay for Therapy Selection

April 28, 2025

Tempus Introduces Loop, an AI-Powered Target Discovery and Validation Platform

April 27, 2025

Tempus Announces 18 Abstracts Accepted for Presentation at the American Association for Cancer Research Annual Meeting 2025

April 24, 2025

Tempus to Report First Quarter 2025 Financial Results on May 6

April 23, 2025

Tempus Signs Expanded Strategic Agreements with AstraZeneca and Pathos to Develop the Largest Multimodal Foundation Model in Oncology

April 22, 2025

Tempus Unveils Advisory Board Featuring Leading Physicians From Across the U.S.

April 17, 2025

Illumina and Tempus partner to drive the future of precision medicine through genomic AI innovation

April 14, 2025

Tempus Exhibits 4 Abstracts at the 2025 American College of Cardiology Annual Meeting

March 28, 2025

Tempus to Present at the 24th Annual Needham Virtual Healthcare Conference

March 25, 2025

Older news releases →

Calls in 2025

Decks in 2025